

Media release – embargoed till 13 March 2013

Clearbridge BioMedics raises S\$9 million Series B led by Vertex Venture

Funds will be used to develop the company's new generation ClearCell™ System

13 March 2013, Singapore – Clearbridge BioMedics today announced that the company has successfully closed a S\$9 million Series B financing. This round of funding was led by Vertex Venture Holdings Ltd, the wholly-owned VC arm of Temasek Holdings. Other investors in this financing round include SPRING Seeds Capital, Clearbridge BSA Pte Ltd and Mr Lu Yoh Chie, and existing shareholder BioVeda. The Series B funds will be used to further develop the company's proprietary ClearCell™ System, which is one of the first non-biomarker based systems commercially available to effectively detect, isolate and retrieve circulating tumour cells (CTCs) from blood.

“Having already entered the cancer research market with its ClearCell™ System, Clearbridge BioMedics is well-positioned to have a tremendous impact on the way healthcare professionals screen, diagnose, treat and monitor cancer patients. Our investment focus has been to invest and build global champions. We see Clearbridge BioMedics, with its leading world class technology platform, as being one of them”, said Mr Chua Joo Hock, Managing Director and Chief Investment Officer, Vertex Venture Management Pte Ltd. Mr Chua, who will be joining the Board of Directors of Clearbridge BioMedics, added: “We welcome Clearbridge BioMedics into our international portfolio of innovative and promising technology companies and look forward to working with the team.”

Clearbridge BioMedics' proprietary ClearCell™ System is sensitive and accurate enough to detect and retrieve CTCs, which can be as rare as a few cells mixed with billions of blood cells in a millilitre of blood. Clearbridge BioMedics will be using this injection of funds to drive the development of its new generation ClearCell™ System, which consists of the ClearCell™ unit and single-use CTChip®.

“Bringing on board these blue-chip investors, including entrepreneur and industry leader, Mr Lu Yoh Chie, is a wonderful validation of the good work by the team” said Mr Johnson Chen, Managing Director and Co-Founder of Clearbridge BioMedics. “We launched our ClearCell™ System for the cancer research market in 2011, and have built up a strong customer base across Asia, Europe and the United States.

Moving forward, we wish to develop the system for further applications. This will involve developing the next generation system to improve its accuracy, sensitivity and reliability. It is a very exciting time for us, and we plan to embark upon validation trials later this year to show the applicability of the ClearCell™ System in a clinical setting.”

In addition to Mr Chua, Clearbridge BioMedics is also expanding its Board of Directors, with Mr Lu, who is the founder of Biosensors International, being appointed Chairman of the Board.

“I am delighted to be joining the Board of Directors and rendering my assistance to the management team. I look forward to playing a role in growing Clearbridge BioMedics into a world leading biomedical company” said Mr Lu.

Set up in late 2009, Clearbridge BioMedics is a spin-off company from the National University of Singapore. In November 2012, Clearbridge BioMedics won all top three awards at the WSJ Asian Innovation Award, which were presented by The Wall Street Journal in partnership with Credit Suisse. The Company’s co-founder/ inventor has also been awarded the prestigious Singapore President’s Technology Award 2011, as well as the NUS Engineering Faculty Research Award 2011 and IES Prestigious Engineering Achievement Award 2010.

Clearbridge BioMedics is ISO13485 certified for the development of cell-based in-vitro diagnostic devices.

- End -

About Clearbridge BioMedics Clearbridge BioMedics specializes in novel platforms with applications in oncology research and diagnostics. It is a National University of Singapore (NUS) spinoff company that is committed to developing medical devices, which will impact the world and revolutionize cancer diagnostics and patient care, by leveraging on ground-breaking technology from research partners.

The ClearCell™ System comprises patent-pending CTChips®, which are microfluidic biochips able to effectively detect, isolate and also retrieve wholly-intact CTCs (Circulating Tumor Cells) from small quantities of patient blood samples. The isolated CTCs can then be stained for identification and enumeration, or retrieved for further molecular analysis. The ClearCell™ System aims to be the next generation of non-invasive “liquid biopsy” approach for cancer screening, diagnosis, staging, personalised medication, and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America.

www.clearbridgebiomedics.com

About Vertex Venture Holdings Vertex Venture Holdings Ltd is a wholly-owned subsidiary of Temasek Holdings, investing in emerging companies throughout Greater Asia and the US.

Since inception in 1988, Vertex has invested in more than 350 start-up companies, achieving substantial returns for investors, while helping over 150 portfolio companies realise their intrinsic value, through listings on capital markets in the US, Europe, Singapore, Hong Kong and Taiwan, and

acquisitions by industry leaders. Headquartered in Singapore, with regional offices in Beijing, Shanghai (China), Taipei (Taiwan), Bangalore (India) and the Silicon Valley (USA), Vertex seeks to leverage the far-reaching network presence and combined experience to create value for both investors and portfolio companies. www.vertexmgt.com

About BioVeda BioVeda Capital is a venture capital firm focused exclusively on investing in healthcare. It has invested in many biomedical companies with leading proprietary technologies and outstanding scientific and management talent. With its headquarters in Singapore and a deep international network, BioVeda has a strong combination of broad scientific and medical expertise, and financial and investment experience to assist partner companies. Its portfolio includes companies in Singapore, China, Britain and the United States - one of which was acquired by Pfizer, another by Roche, and two that went public on NASDAQ. www.biovedavc.com

About Clearbridge BSA Pte Ltd As part of the Research, Innovation and Enterprise (RIE) 2015 plan, the Singapore government has approved the establishment of Sector Specific Accelerators (SSA) to identify, invest and grow start-ups in strategic but nascent sectors, starting with the Biomedical Science Sector. S\$40 million has been set aside to pilot the SSA initiative via the Biomedical Science Accelerator (BSA) with an initial focus on the Medical Technology subsector. Clearbridge BSA Pte Ltd has been appointed as one of two BSA operator. SPRING SEEDS Capital (SSC), the manager of the BSA Programme, will co-invest in the start-ups identified by Clearbridge BSA on a 1:1 basis. www.clearbridgebsa.com

About SPRING SEEDS Capital SPRING SEEDS Capital, an investment arm of SPRING Singapore, co-invests with independent investor(s) into commercially viable Singapore-based start-ups with innovative and strong intellectual content that are scalable across international markets. It currently manages 3 funds under its portfolio - SPRING Start-up Enterprise Development Scheme (SPRING SEEDS), Business Angel Scheme (BAS) and the Biomedical Sciences Accelerator (BSA). For more information on the funding programs, please visit www.spring.gov.sg

Media enquiries can be directed to:
Chan Yiu Lin (Ms)
Greener Grass Communications
Mobile: (65) 9-765 5897
Email: media@clearbridgeaccelerator.com